CompletedNot Applicable

Impact of Prisma on Donor Site Pain

United States17 participantsStarted 2019-11-07

Plain-language summary

The purpose of this study is to assess the feasibility of evaluating the use of a composite collagen, silver-oxidized regenerated cellulose matrix compared to the standard of care dressing on donor site pain for patients undergoing split-thickness skin grafting in preparation for a larger study.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient scheduled to undergo STSG for any reason * Patient, or designated healthcare proxy, has read and signed the IRB-approved informed consent form. Exclusion Criteria: * Active infection or history of radiation to the donor site * Patient has a known sensitivity to Promogran Prisma™ or silver * Elevated INR \>3.0 * Insensate at the donor site * Chronic narcotic use (\>6 months of daily use)

What they're measuring

Pain Score on Visual Analogue Scale (VAS)

Timeframe: Postoperative Day 1

Trial details

NCT IDNCT04050124

SponsorNYU Langone Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-11-29

Results submitted2024-03-20

View on ClinicalTrials.gov More Skin Graft Disorder trials